These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3856798)

  • 1. A study into the mucosal absorption of isosorbide dinitrate at different intraoral sites.
    Pimlott SJ; Addy M
    Oral Surg Oral Med Oral Pathol; 1985 Feb; 59(2):145-8. PubMed ID: 3856798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
    Straehl P; Galeazzi RL
    Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of isosorbide dinitrate spray on central hemodynamics. Comparison with sublingual glyceryl trinitrate and isosorbide dinitrate.
    Saito M; Fukami K; Sumiyoshi T; Haze K; Hiramori K
    Arzneimittelforschung; 1984; 34(6):707-9. PubMed ID: 6435644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.
    Mansel-Jones D; Taylor T; Doyle E; Chasseaud LF; Darragh A; O'Kelly DA; Over H
    J Clin Pharmacol; 1978; 18(11-12):544-8. PubMed ID: 721951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative determination of isosorbide dinitrate and two metabolites in plasma.
    Chin DA; Prue DG; Michelucci J; Kho BT; Warner CR
    J Pharm Sci; 1977 Aug; 66(8):1143-5. PubMed ID: 894502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.
    Laufen H; Leitold M
    Arzneimittelforschung; 1992 Jul; 42(7):931-5. PubMed ID: 1418058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of a new formulation of isosorbide dinitrate oral spray and sublingual nitroglycerin tablets.
    Marmor A
    Am J Cardiol; 1990 Jun; 65(21):43J-45J. PubMed ID: 2112337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
    Thomson AH; Miller SH; Green ST; Whiting B
    Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
    Fung HL
    Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
    Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
    J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
    Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Bechtold H; Meinertz T; Fung HL
    Clin Pharmacol Ther; 1983 Jun; 33(6):747-56. PubMed ID: 6851405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of disease, route of administration, cigarette smoking, food intake on the pharmacokinetics and circulatory effects of isosorbide dinitrate.
    Fung HL; Ruggirello D; Stone JA; Parker JO
    Z Kardiol; 1983; 72 Suppl 3():5-10. PubMed ID: 6666234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and tissue levels of [14C]isosorbide dinitrate after oral and intravenous administration to rat.
    Reed DE; Akester JM; Prather JF; Tuckosh JR; McCurdy DH; Yeh C
    J Pharmacol Exp Ther; 1977 Jul; 202(1):32-7. PubMed ID: 874817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs.
    Cayen MN; Hicks D; Karounis J; Dvornik D
    J Pharm Pharmacol; 1983 May; 35(5):312-6. PubMed ID: 6134800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous isosorbide-dinitrate.
    Platzer R; Reutemann G; Galeazzi RL
    J Pharmacokinet Biopharm; 1982 Dec; 10(6):575-86. PubMed ID: 7182455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
    Laufen H; Aumann M; Leitold M
    Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemodynamics and plasma concentrations following sublingual GTN and intravenous, or inhaled, isosorbide dinitrate.
    Culling W; Singh H; Bashir A; Griffiths BE; Dalal JJ; Sheridan DJ
    Br J Clin Pharmacol; 1984 Feb; 17(2):125-31. PubMed ID: 6422972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrate cross-tolerance: effect of sublingual isosorbide dinitrate and nitroglycerin during sustained nitrate therapy.
    Dalal JJ; Parker JO
    Am J Cardiol; 1984 Aug; 54(3):286-8. PubMed ID: 6431795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.